At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study entitled “Gene Expression–based Subtyping of Early Triple-Negative Breast Cancer for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial” (Abstract No. RF3-02) was presented. This study provides an in-depth analysis of the heterogeneity of benefit from immunotherapy in early-stage triple-negative breast cancer (TNBC), highlighting the predictive value of tumor-infiltrating lymphocytes (TILs) and TNBC molecular subtypes. Oncology Frontier invited Professor Jin Feng and his colleagues Professor Yu Xinmiao and Professor Zheng Ang from the First Hospital of China Medical University to introduce and comment on the study in detail, offering important evidence and clinical insights for precision immunotherapy in TNBC.

Editor's Note: The 48th San Antonio Breast Cancer Symposium (SABCS 2025) was held from December 9–12 in San Antonio, Texas, USA. As one of the world’s most influential academic meetings…

Editor’s Note The 48th San Antonio Breast Cancer Symposium (SABCS) was held in San Antonio, USA, from December 9 to 12, 2025. A retrospective study led by Professor Mao Xiaoyun…

Editor’s note: For patients with HER2-positive breast cancer, neoadjuvant treatment strategies are rapidly evolving—from traditional dual HER2 blockade to the fast-emerging era of antibody–drug conjugates (ADCs). Recently, Chinese-developed anti-HER2 ADCs…

Editor’s Note: Estrogen receptor (ER)–positive breast cancer has long been regarded as a relatively “indolent” subtype. However, during disease progression, a subset of patients experience loss of ER expression, converting…

Editor’s Note As CDK4/6 inhibitors (CDK4/6i) secure their role in adjuvant therapy for HR+/HER2− early breast cancer, a central clinical challenge has emerged: how to maximize benefit while minimizing toxicity…

Editor’s Note: As CDK4/6 inhibitors (CDK4/6i) secure their role in adjuvant therapy for HR+/HER2− early breast cancer, a central clinical challenge has emerged: how to maximize benefit while minimizing toxicity…

Editor’s Note: In recent years, systemic treatment options for HER2-positive breast cancer brain metastases have made meaningful progress, yet substantial unmet clinical needs remain. At the 2025 San Antonio Breast…

Editor's Note: HER2-positive breast cancer has a high incidence of brain metastases. In the era when treatment relied primarily on local therapies, patient survival outcomes were poor. The PERMEATE study…